

**"R.S"**

Dedicated to my spiritual Guru


***Parama Premamaya Sri Sri Thakur Anukulchandra***

## **DECLARATION BY THE CANDIDATE**

I hereby declare that the thesis entitled “**Studies on *Bungarus fasciatus* venom from Eastern and North East India and characterization of poorly immunodepleted PLA<sub>2</sub> enzymes**” submitted to School of Sciences, Tezpur University, in part fulfilment for the award of the degree of **Doctor of Philosophy** in the Department of Molecular Biology and Biotechnology, is a record of original research work carried out by me. Further, I declare that no part of this thesis has been reproduced elsewhere for award of any other degree.

**Place:** Tezpur

**Date:** 08-07-2024

  
(Amit Talukdar)

**Registration No.:** TZ201043 of 2019



# TEZPUR UNIVERSITY

(A Central University established by an Act of Parliament in 1994)

Department of Molecular Biology and Biotechnology

Napaam, Tezpur- 784028, Assam, India

**Dr. Robin Doley, Ph.D**

**Professor**

**Department of Molecular Biology and Biotechnology**

**Ph. No. 03712-275412(O)**

**E-mail: [doley@tezu.ernet.in](mailto:doley@tezu.ernet.in)**

## CERTIFICATE OF THE PRINCIPAL SUPERVISOR

This is to certify that the thesis entitled “**Studies on *Bungarus fasciatus* venom from Eastern and North East India and characterization of poorly immunodepleted PLA<sub>2</sub> enzymes**” submitted to the School of Sciences, Tezpur University in part fulfilment for the award of the degree of Doctor of Philosophy in Molecular Biology and Biotechnology is a record of original research work carried out by **Mr. Amit Talukdar** under my supervision and guidance.

All help received by him from various sources have been duly acknowledged. No part of this thesis has been submitted elsewhere for award of any other degree.

**(Dr. Robin Doley)**

**Place: Tezpur**

**Date: 08-07-2024**

**Principal Supervisor**

## **ACKNOWLEDGEMENT**

I would like to express my deepest gratitude to my Ph.D supervisor Prof. Robin Doley for his expert guidance, support and encouragement throughout my research journey. His expertise, unwavering dedication and commitment played a crucial role in the success of my experiments and the completion of my thesis.

I extend my heartfelt gratitude to the Hon'ble Vice Chancellor of Tezpur University and the university administration for their visionary leadership and unwavering support throughout my academic journey.

I am grateful to the Head of the Department, Department of MBBT for his dedication to providing resources and opportunities that have greatly enhanced my research experience and enabled me to fulfil my research objectives.

I would like to thank my doctoral committee members Dr. Rupak Mukhopadhyay and Dr. Jyoti Prasad Saikia for their insightful feedback, constructive comments and support to my research work.

I am thankful to Council of Scientific & Industrial Research (CSIR), India for providing financial assistance in the form of Junior Research Fellowship (CSIR-JRF) and Senior Research Fellowship (CSIR-SRF).

I extend my sincere gratitude to Prof. Anita Malhotra, Bangor University, UK and Dr. H. T. Lalremsanga, Mizoram University, for providing venom samples and reviewing the manuscripts. I also extend my thanks to Dr. Dayal Bandhu Majumdar, Calcutta National Medical College & Hospital, Kolkata, West Bengal for providing venom samples.

I would like to specially thank Prof. Suvendra Kumar Ray, Dr. Nabajyoti Medhi and Dr. Arup Roy of Tezpur University for their constant support and encouragement.

I am deeply grateful to all my Teachers who have contributed at some point of my life in shaping my educational journey and character.

I would like to thank the non-teaching staff of the department for their help and support in various departmental activities and documentation work.

I would like to thank all my Ph.D batchmates and friends for their support and encouragement. I am immensely grateful to my friend Ms. Mandira Basumatary for her unwavering support, kindness and encouragement that has been a constant source of strength through various ups and downs in my journey.

I am deeply grateful to my friend Ms. Priya Maddhesiya whose friendship and encouragement kept me motivated. I am thankful to her for being a constant source of wisdom and being a true well-wisher.

I am truly grateful to my lab seniors Dr. Simran Kaur, Dr. Archana Deka, Dr. Arpita Devi, Dr. Rafika Yasmin and Dr. Susmita Thakur for sharing their knowledge and expertise with me. I also thank my labmates Mahari, Jyotirmoy, Nyumpi, Plabita, Shristi and Parishmita for their constant support and co-operation in the lab.

My heartfelt gratitude goes to my parents Mrs. Anita Talukdar and Late. Bidhan Chandra Talukdar, and also to my elder brother Binit Talukdar, for their unwavering love, selfless sacrifices and heartfelt blessings. I would also like to bow down to my maternal grandparents Shri Joydeb Saha and Smt. Arati Saha for their unconditional love and constant support that has been the greatest gift I could ever receive. My family, through their prayers, teachings and examples, have instilled in me a deep sense of gratitude, compassion, and reverence for the divine.

Finally, I would like to bow down to the lotus feet of my spiritual guru *Prarama Premamaya Sri Sri Thakur Anukulchandra*, and his family *Parama Pujaniya Sri Sri Boroma* and *Parama Pujiyapada Sri Sri Borda* for their divine blessings throughout my life, and without whom I would not have reached where I am today. I also bow down to *Param Pujiyapada Sri Sri Acharyadeb* whose immense love and guidance in my life has shown me clarity and inspired me to follow my *dharma* with vigour. I bow down to our beloved youth icon *Pujaniya Sri Sri Abin dada* whose divine smile, wisdom and ‘ocean of love’ have always motivated me to follow *Sri Sri Thakur*’s philosophy of “*being and becoming*”.

- **Amit Talukdar**

## List of Figures

	Figures	Page
<b>Chapter 1</b>		
Figure 1.1	Krait species found in India.	4
Figure 1.2	Distribution map of <i>B. fasciatus</i> .	5
Figure 1.3	Critical steps involved in manufacturing of safe and effective polyvalent antivenom followed by its subsequent infusion in envenomated patients in India.	10
Figure 1.4	Intra-specific venom variation of <i>B. fasciatus</i> from seven different countries. A. Vietnam, B. Malaysia, C. India, D. Thailand, E. Indonesia, F. Myanmar, and G. China.	18
Figure 1.5	Flow-chart of research objectives.	22
<b>Chapter 2</b>		
Figure 2.1	<i>B. fasciatus</i> venom collection locations of Hooghly (West Bengal; in purple color), Aizawl (Mizoram; in dark blue), and Guwahati (Assam; in light blue).	24
Figure 2.2	SDS-PAGE gel showing the venom profiles of <i>B. fasciatus</i> .	32
Figure 2.3	Chromatography profile of crude venoms of <i>B. fasciatus</i> and the congeneric “Big-Four” snake <i>B. caeruleus</i> (Tamil Nadu, India) after RP-HPLC analysis. The profiles were grouped into 6 zones (A to F) for the convenience of description.	33
Figure 2.4	PLA <sub>2</sub> activity of <i>B. fasciatus</i> venoms estimated using turbidometric method.	35
Figure 2.5	PLA <sub>2</sub> activity of <i>B. fasciatus</i> venoms estimated by sPLA <sub>2</sub> kit (colorimetric method).	36
Figure 2.6	Fibrinogenolytic activity of crude venoms of <i>B. fasciatus</i> from Eastern and North-East India.	36
Figure 2.7	Caseinolytic activity of crude <i>B. fasciatus</i> venoms.	37
Figure 2.8	Direct hemolytic activity of crude <i>B. fasciatus</i> venoms.	38
Figure 2.9	Indirect hemolytic activity of crude <i>B. fasciatus</i> venoms.	38
Figure 2.10	Recalcification Time (RT) of crude <i>B. fasciatus</i> venoms.	39
Figure 2.11	Prothrombin Time (PT) of crude <i>B. fasciatus</i> venoms.	40

Figure 2.12	APTT of crude <i>B. fasciatus</i> venoms.	40
-------------	---	----

### Chapter 3

Figure 3.1	Indian polyvalent antivenom used for the study. A. VINS polyvalent antivenom (VPAV), B. Premium Serums polyvalent antivenom (PSPAV), C. Bharat Serums polyvalent antivenom (BSPAV).	47
Figure 3.2	A. Gel electrophoresis profile of Indian polyvalent antivenom (12.5% Tris-glycine gel) under reducing (R) and non-reducing (NR) conditions. B. Structure of whole IgG molecule and its fragments F(ab') <sub>2</sub> , Fab, single chain variable fragment (scFv) and single-domain antibody fragment (sdAbs).	52
Figure 3.3	Western blot of three polyvalent antivenoms manufactured in India against the venom of <i>Bungarus fasciatus</i> . A. Premium Serums; B. VINS; C. Bharat Serums. Pre-stained protein marker (PageRuler plus, Thermo Scientific, USA) was utilized as the reference ladder.	54
Figure 3.4	Analysis of Bharat Serums polyvalent antivenom's immunodepletion potential against <i>Bungarus fasciatus</i> venoms utilizing second-generation antivenomics.	55

### Chapter 4

Figure 4.1	The immunodepletion profile of Premium Serums polyvalent antivenom against <i>B. fasciatus</i> venom from Aizawl, Mizoram.	70
Figure 4.2	The immunodepletion profile of Premium Serums polyvalent antivenom against <i>B. fasciatus</i> venom from Guwahati, Assam.	73
Figure 4.3	(A). 12.5% Glycine gel profile of crude venom and P5, P6 and P7 peaks from the venom of <i>B. fasciatus</i> (Guwahati, Assam). The wells were loaded with 15 µg of crude venom or poorly-immunodepleted proteins (P5, P6 and P7); (B). Immunoblot profile of crude venom and peaks (P5, P6 and P7) after western blotting utilizing Indian polyvalent antivenom (Premium Serums).	75

### Chapter 5

Figure 5.1	sPLA <sub>2</sub> activity of crude venom and poorly-immunodepleted P5, P6 and P7 peaks from <i>B. fasciatus</i> venom (Guwahati, Assam).	89
Figure 5.2	Determination of anticoagulant activity of <i>B. fasciatus</i> venom and poorly-immunodepleted P5, P6 and P7 peaks. (A). RT, (B). PT, and (C). APTT.	90
Figure 5.3	In vitro neutralization of enzymatic activities of <i>B. fasciatus</i> venom and P5, P6 and P7 peaks by Indian polyvalent antivenom (Premium	91

	Serums).	
Figure 5.4	Multiple sequence alignment of identified phospholipase A <sub>2</sub> enzymes from poorly-immunodepleted P5, P6 and P7 peaks of <i>B. fasciatus</i> . Two PLA <sub>2</sub> (Q6SLM0 and C0HK16) from “Big-Four” snakes were taken as the control.	92
Figure 5.5	Phylogenetic Tree of identified PLA <sub>2</sub> enzymes from <i>B. fasciatus</i> (Guwahati, Assam) and known PLA <sub>2</sub> proteins from Indian “Big-Four” snakes.	94
Figure 5.6	Homology modelling and structure prediction of identified PLA <sub>2</sub> enzymes using SWISS-MODEL-Expasy server. Ribbon model of PLA <sub>2</sub> enzymes (A) Q90WA8; (B) P14411; (C) P0C551; (D) Q90WA7; (E) ABU63161; (F) A6MEY4; (G) ABU63164; (H) C0HK16; (I) Q6SLM0.	95
Figure 5.7	Validation of modelled structure of identified PLA <sub>2</sub> enzymes. (A) Q90WA8; (B) P14411; (C) P0C551; (D) Q90WA7; (E) ABU63161; (F) A6MEY4; (G) ABU63164; (H) C0HK16; (I) Q6SLM0.	96
Figure 5.8	Predicted tertiary structure of Conformational B-cell epitopes (Ball structure) on surface structure of PLA <sub>2</sub> enzyme (P0C551) and Positive controls from “Big-Four” snakes.	101
Figure 5.9	Predicted surface cavity of identified PLA <sub>2</sub> enzymes from <i>B. fasciatus</i> venom (Guwahati, Assam) using CASTp 3.0 webserver. PLA <sub>2</sub> accession number (A) Q90WA8; (B) P14411; (C) P0C551; (D) Q90WA7; (E) ABU63161; (F) A6MEY4; (G) ABU63164. The predicted surface pocket is depicted in red colored spheres.	102

## Chapter 6

Figure 6.1	Flow-chart to improve efficacy of polyvalent antivenom manufactured in India against the venom of <i>B. fasciatus</i> from North-East India by inclusion of poorly-immunodepleted PLA <sub>2</sub> enzymes in the venom pool used for antivenom production.	114
------------	---	-----



## List of Tables

Table no.	Figure name	Page No.
<b>Chapter 1</b>		
Table 1.1	Superfamilies of snake venom.	15
<b>Chapter 2</b>		
Table 2.1	Estimation of protein concentration of crude <i>B. fasciatus</i> venom.	32
Table 2.2	Number of peaks eluted in RP-HPLC profiles at different time-intervals (depicted as Zones).	34
<b>Chapter 3</b>		
Table 3.1	Estimation of total F(ab') <sub>2</sub> content in commercially available Indian polyvalent antivenom.	53
Table 3.2	The chromatographic area of peaks of crude venom (Vi), non-retained (NRi) and retained (Ri) fractions are listed in this table. The percentage of non-retained fractions of individual peaks (%NRi (peak)) and the venom sample (%NRi (venom)) after second-generation antivenomics study using polyvalent antivenom (Bharat Serums) was obtained.	56
<b>Chapter 4</b>		
Table 4.1	Amount of <i>B. fasciatus</i> venom (Aizawl, Mizoram) retained after immunodepletion using polyvalent antivenom (Premium Serums) and determination of %Maximum binding of individual peaks and venom.	71
Table 4.2	Amount of <i>B. fasciatus</i> venom (Guwahati) retained after immunodepletion using polyvalent antivenom (Premium Serums) and determination of %Maximum binding of individual peaks and venom.	74
Table 4.3	Estimation of antivenom vials required and associated cost to immunocapture all venom proteins of <i>B. fasciatus</i> using Premium Serums polyvalent antivenom.	75
Table 4.4	Summary of proteins/peptides identified from poorly-immunodepleted peaks of <i>B. fasciatus</i> venom (Guwahati) after examination by ESI-LC-MS/MS.	76-78
Table 4.5	Pairwise sequence alignment of partial peptide fragments from poorly-immunodepleted peaks (P5, P6 and P7) with their homologous protein (using NCBI BLASTp).	78-79

## Chapter 5

Table 5.1	Percent identity matrix of seven identified PLA <sub>2</sub> enzymes from <i>B. fasciatus</i> venom (Guwahati, Assam).	92
Table 5.2	Comparative analysis of secondary structure of seven identified PLA <sub>2</sub> enzymes from <i>B. fasciatus</i> venom (Guwahati, Assam).	93
Table 5.3	Validation of modelled structure by GMQE, MolProbity score, Clash score, Ramachandran plot and ERRAT quality factor.	96
Table 5.4	Prediction of linear B-cell epitopes of seven identified PLA <sub>2</sub> enzymes from <i>B. fasciatus</i> venom (Guwahati, Assam) using Bepipred 2.0.	97-98
Table 5.5	Prediction of conformational B-cell epitopes of seven identified PLA <sub>2</sub> enzymes from <i>B. fasciatus</i> venom (Guwahati, Assam) using Ellipro.	98-100
Table 5.6	Area and Volume of predicted surface cavity in identified PLA <sub>2</sub> enzymes, and their vicinity to active and/or Ca <sup>2+</sup> -binding sites.	102

## **List of Keywords**

- Chapter 1 Banded krait, *Bungarus fasciatus*, Kraits, Snake envenomation, Antivenom therapy, Pre-synaptic and post-synaptic neurotoxins
- Chapter 2 Venom variation, PLA<sub>2</sub> activity, Fibrinogenolytic activity, Caseinolytic activity, Hemolytic activity, Anticoagulant activity
- Chapter 3 Antivenom cross-reactivity, Indian polyvalent antivenom, Second-generation antivenomics, Retained and non-retained fraction, Immunodepletion ability, Total IgG content, Bharat Serums polyvalent antivenom
- Chapter 4 Third –generation antivenomics, Maximum binding capability, In-gel trypsin digestion, Protein identification, Affinity column, Poorly-immunodepleted peaks, Premium Serums polyvalent antivenom
- Chapter 5 PLA<sub>2</sub> enzymes, Enzymatic activity, *In silico* characterization, Tertiary structure prediction, B-cell epitope prediction, Surface cavity search
- Chapter 6 Region-specific antivenom, Recombinant antivenom, Monoclonal antibodies, Single-chain variable fragments, Single-domain antibodies, ADDomer nanoparticles

## List of Symbols and Abbreviations

%	Percent
<	Lesser Than
>	Greater Than
=	Equals to
&	And
±	Plus or Minus
Σ	Summation
Å	Angstrom
°C	Degree Celsius
μ	Micron
μg	Microgram
μl	Microlitre
μm	Micrometer
μmol	Micromolar
2G	Second-generation
3D	Three Dimensional
3G	Third-generation
3FTx	Three-Finger Toxin
5'-NUC	5'-Nucleotidase
AChE	Acetylcholinesterase
AMD	Age-Related Macular Degeneration
ANOVA	Analysis of Variance
APS	Ammonium Persulphate
APTT	Activated Partial Thromboplastin Time
BCAV	<i>Bungarus candidus</i> Antivenom
BCIP	5-bromo-4-chloro-3-indolyl-phosphate
BF-CT1	<i>Bungarus fasciatus</i> Cytotoxin-1
BFMAV	<i>Bungarus fasciatus</i> Monovalent Antivenom
BME	2-mercaptoethanol
bnAb	Broadly Neutralizing Antibody
BLASTp	Basic Local Alignment Search Tool-protein

BSA	Bovine Serum Albumin
BSPA V	Bharat Serums Polyvalent Antivenom
CaCl <sub>2</sub>	Calcium Chloride
CASTp	Computed Atlas of Surface Topography of proteins
CE	Collision Energy
CNBr	Cyanogen Bromide
Co.	Company
CRiSP	Cysteine-Rich Secretory Proteins
CTL	Snake C-Type Lectins
CTX	Cytotoxin
CV	Column Volume
DCE	Directed Chemical Evolution
DLF	Direct Lytic Factor
DTNB	5,5'-Dithiobis(2-nitrobenzoic acid)
E	East
ED <sub>50</sub>	Median Effective Dose
ELISA	Enzyme-Linked Immunosorbant Assay
ESI	Electrospray Ionization
eV	Electron volt
FHAV	Freeze-Dried Hemorrhagic Antivenom
Fc	Fragment constant
FNAV	Freeze-Dried Neurotoxic Antivenom
FWHM	Full Width at Half Maximum
g	Gram
GMQE	Global Model Quality Estimate
h	Hour
HBS	Habu Serum Factor
HIV	Human Immunodeficiency Virus
HR	Hemorrhagin
<i>i.e.</i>	That is
Ig	Immunoglobulin
<i>i.v</i>	Intravenous
INR	Indian Rupee

ISCICS	Irula Snake Catchers' Industrial Cooperative Society
KCl	Potassium Chloride
kDa	kiloDalton
km	kilometer
KSPI	Kunitz-type Serine Protease Inhibitor
kV	kiloVolt
LAAO	L-Amino Acid Oxidases
LC-MS/MS	Liquid Chromatography-Tandem Mass spectrometry
LD <sub>50</sub>	Median Lethal Dose
Ltd.	Limited
M	Molar
m	Meter
mA	Milliampere
MALDI-TOF	Matrix Assisted Laser Desorption Ionization-Time of Flight
MeCN	Acetonitrile
mg	Milligram
min	Minute
ml	Millilitre
mm	Millimeter
mM	Millimolar
MS	Mass spectrometry
MW	Molecular weight
MWCO	Molecular weight Cut-off
m/z	Mass-by-Charge ratio
N	North
NaCl	Sodium Chloride
NaHCO <sub>3</sub>	Sodium Bicarbonate
NAMAV	<i>Naja atra</i> Monovalent Antivenom
NBAV	Neuro Bivalent Antivenom
NBT	Nitro Blue Tetrazolium
NCBI	National Center for Biotechnology Information
NCT	Normal Clotting Time
NH <sub>4</sub> CO <sub>3</sub>	Ammonium Carbonate

nm	Nanometer
No.	Number
n-P	Neutralization Potency
NPAV	Neuro Polyvalent Antivenom
NRi	Non-retained fraction for peak i
O.D	Optical Density
OHMAV	<i>Ophiophagus hannah</i> Monovalent antivenom
OHVA-PLA <sub>2</sub>	<i>Ophiophagus hannah</i> venom acidic Phospholipase A <sub>2</sub>
PAGE	Poly-Acrylamide Gel Electrophoresis
PBS	Phosphate-Buffered Saline
PLA <sub>2</sub>	Phospholipase A <sub>2</sub>
PPP	Platelet-Poor Plasma
PSPAV	Premium Serums Polyvalent Antivenom
PT	Prothrombin Time
PVDF	Polyvinylidene Difluoride
Pvt.	Private
RBC	Red Blood Cell
Ri	Retained fraction for peak i
ROC	Republic of China
RP-HPLC	Reverse-Phase High Performance Liquid Chromatography
rpm	Revolutions per minute
RT	Recalcification Time
s	Second
SABU	Serum Anti Bisa Ular
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus-2
scFv	Single Chain Variable fragment
sdAb	Single-Domain Antibody fragment
SDS	Sodium Dodecyl Sulphate
S.E	Standard Error
SELEX	Systematic Evolution of Ligands by Exponential enrichment
SOP	Standard Operating Procedure
sPLA <sub>2</sub>	Secreted Phospholipase A <sub>2</sub>
Snaclecs	Snake c-type lectin-like proteins

SSI	Small Synthetic Inhibitor
SVHY	Snake Venom Hyaluronidase
SVMP	Snake Venom Metalloproteinase
SVSP	Snake Venom Serine Protease
TBS	Tris-Buffered Saline
TBST	Tris-Buffered Saline with Tween 20
TCA	Trichloroacetic Acid
TEMED	N,N,N',N'-tetramethylethylenediamine
TFA	Trifluoroacetic Acid
USA	United States of America
US FDA	United States Food and Drug Administration
V	Volt
VEGF	Vascular Endothelial Growth Factor
V <sub>H</sub> H	Heavy-Chain Variable Domain
V <sub>i</sub>	Chromatographic area of peak i
VICC	Venom Induced Consumption Coagulopathy
VNGF	Vascular Nerve Growth Factor
VPAV	VINS Polyvalent Antivenom
v/v	Volume per volume
WHO	World Health Organization